CN112154208B - 产生改进的病毒和非病毒纳米质粒载体 - Google Patents

产生改进的病毒和非病毒纳米质粒载体 Download PDF

Info

Publication number
CN112154208B
CN112154208B CN201980034026.9A CN201980034026A CN112154208B CN 112154208 B CN112154208 B CN 112154208B CN 201980034026 A CN201980034026 A CN 201980034026A CN 112154208 B CN112154208 B CN 112154208B
Authority
CN
China
Prior art keywords
rna
replication
seq
origin
vectors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980034026.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN112154208A (zh
Inventor
詹姆斯·A·威廉姆斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aldeflon LLC
Original Assignee
Aldeflon LLC
Nature Technology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aldeflon LLC, Nature Technology Corp filed Critical Aldeflon LLC
Priority to CN202510450562.4A priority Critical patent/CN120249340A/zh
Publication of CN112154208A publication Critical patent/CN112154208A/zh
Application granted granted Critical
Publication of CN112154208B publication Critical patent/CN112154208B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15051—Methods of production or purification of viral material
    • C12N2740/15052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/101—Plasmid DNA for bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/24—Vectors characterised by the absence of particular element, e.g. selectable marker, viral origin of replication
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/90—Vectors containing a transposable element
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2820/00—Vectors comprising a special origin of replication system
    • C12N2820/55—Vectors comprising a special origin of replication system from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/185—Escherichia
    • C12R2001/19—Escherichia coli

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Carbon And Carbon Compounds (AREA)
CN201980034026.9A 2018-03-21 2019-03-20 产生改进的病毒和非病毒纳米质粒载体 Active CN112154208B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202510450562.4A CN120249340A (zh) 2018-03-21 2019-03-20 产生改进的病毒和非病毒纳米质粒载体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862645892P 2018-03-21 2018-03-21
US62/645,892 2018-03-21
PCT/US2019/023209 WO2019183248A1 (en) 2018-03-21 2019-03-20 Viral and non-viral nanoplasmid vectors with improved production

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202510450562.4A Division CN120249340A (zh) 2018-03-21 2019-03-20 产生改进的病毒和非病毒纳米质粒载体

Publications (2)

Publication Number Publication Date
CN112154208A CN112154208A (zh) 2020-12-29
CN112154208B true CN112154208B (zh) 2025-04-15

Family

ID=66001381

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201980034026.9A Active CN112154208B (zh) 2018-03-21 2019-03-20 产生改进的病毒和非病毒纳米质粒载体
CN202510450562.4A Pending CN120249340A (zh) 2018-03-21 2019-03-20 产生改进的病毒和非病毒纳米质粒载体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202510450562.4A Pending CN120249340A (zh) 2018-03-21 2019-03-20 产生改进的病毒和非病毒纳米质粒载体

Country Status (13)

Country Link
US (1) US12600984B2 (https=)
EP (2) EP3768846B1 (https=)
JP (2) JP7520719B2 (https=)
KR (1) KR20210016330A (https=)
CN (2) CN112154208B (https=)
AU (2) AU2019240068B2 (https=)
CA (1) CA3093346A1 (https=)
DK (1) DK3768846T5 (https=)
ES (1) ES2950736T3 (https=)
FI (1) FI3768846T3 (https=)
LT (1) LT3768846T (https=)
SG (1) SG11202009009UA (https=)
WO (1) WO2019183248A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019183248A1 (en) * 2018-03-21 2019-09-26 Nature Technology Corporation Viral and non-viral nanoplasmid vectors with improved production
US20220042038A1 (en) * 2018-12-20 2022-02-10 Poseida Therapeutics, Inc. Nanotransposon compositions and methods of use
GB2700048B (en) 2019-09-18 2026-03-04 Aldevron Llc synthetic dna vectors and method of use
JP7833134B2 (ja) * 2020-03-11 2026-03-19 アルデブロン，エル．エル．シー． 細菌宿主株
CA3201499A1 (en) 2020-11-13 2022-05-19 Catamaran Bio, Inc. Genetically modified natural killer cells and methods of use thereof
CA3223292A1 (en) 2021-06-25 2022-12-29 Laura Van Lieshout Adeno-associated virus packaging systems
US20250114452A1 (en) 2021-08-04 2025-04-10 The Regents Of The University Of Colorado, A Body Corporate Lat activating chimeric antigen receptor t cells and methods of use thereof
CN114045305B (zh) * 2021-10-15 2023-03-24 深圳市深研生物科技有限公司 多转座子系统
WO2023114901A2 (en) 2021-12-15 2023-06-22 Oxford Biomedica Solutions Llc Methods and compositions for the production of adeno-associated virus
WO2023172514A1 (en) 2022-03-07 2023-09-14 Catamaran Bio, Inc. Engineered immune cell therapeutics targeted to her2 and methods of use thereof
US20250354159A1 (en) * 2022-06-13 2025-11-20 Nanjing GenScript Biotech Co., Ltd. Wild-type-mutant pi protein switching expression system capable of increasing efficiency of preparing screening-tag-free plasmid
JP2025525583A (ja) 2022-07-19 2025-08-05 ランパート バイオサイエンス インコーポレイテッド 非免疫原性環状非ウイルス性ｄｎａベクター
CN117305339B (zh) * 2023-11-30 2024-02-06 苏州左旋星生物科技有限公司 优化大肠杆菌基因编辑的载体及其应用
WO2025160245A1 (en) 2024-01-25 2025-07-31 Aldevron, L.L.C. Viral and non-viral nanoplasmid vectors with improved production
WO2025231315A2 (en) 2024-05-03 2025-11-06 Aldevron, L.L.C. Bacterial host strains
WO2026076187A1 (en) * 2024-10-03 2026-04-09 Aldevron, L.L.C. Compositions and methods for microbial production of antibiotic-free closed-ended linear dna

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04197185A (ja) * 1990-11-28 1992-07-16 Mitsui Toatsu Chem Inc 酵母発現ベクター及びこれを用いた誘導的発現
GB9506051D0 (en) * 1995-03-24 1995-05-10 Univ Singapore Gene expression
FR2738842B1 (fr) 1995-09-15 1997-10-31 Rhone Poulenc Rorer Sa Molecule d'adn circulaire a origine de replication conditionnelle, leur procede de preparation et leur utilisation en therapie genique
US7279313B2 (en) 1995-09-15 2007-10-09 Centelion Circular DNA molecule having a conditional origin of replication, process for their preparation and their use in gene therapy
US5922583A (en) 1995-10-17 1999-07-13 Biostar Inc. Methods for production of recombinant plasmids
US6709844B1 (en) * 2000-11-16 2004-03-23 Mannkind Corporation Avoidance of undesirable replication intermediates in plasmid propagation
JP2004267001A (ja) * 2000-08-16 2004-09-30 Kansai Tlo Kk トランスジェニック哺乳動物及びその作製方法並びにこれを用いた遺伝子機能の解明方法
UY26317A1 (es) * 2000-08-30 2000-10-31 Alfonso Cayota Carlos Pritsch Sistema de produccion de trombopoyetina humana por celulas de mamiferos en cultivo
FR2821855B1 (fr) 2001-03-09 2004-04-02 Cayla Genes synthetiques et plasmides bacteriens depourvus de cpg
CA2794446C (en) * 2001-04-04 2015-09-08 Genencor International, Inc. Uncoupled productive and catabolic host cell pathways
US20060088837A1 (en) * 2002-04-26 2006-04-27 Kazunari Taira Expression system for stem-loop rna molecule having rnai effect
WO2005003359A1 (ja) * 2003-07-08 2005-01-13 Japan Science And Technology Corporation トランスジェニック生物を作製する方法およびシステム
GB0327056D0 (en) 2003-11-20 2003-12-24 Cobra Biolog Ltd Plasmid maintenance
MX2007001889A (es) 2004-08-19 2007-05-09 Nature Technology Corp Proceso para la fermentacion de adn de plasmido.
CA2577519A1 (en) * 2004-08-23 2006-03-30 Nucleonics, Inc. Multiple rna polymerase iii promoter expression constructs
TWI311152B (en) 2004-09-17 2009-06-21 Boehringer Ingelheim Rcv Gmbh & Co K Host-vector system for antibiotic-free cole1 plasmid propagation
US9018012B2 (en) 2005-01-20 2015-04-28 Nature Technology Corporation Vectors and methods for genetic immunization
EP1921140B1 (en) 2005-07-05 2011-12-14 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Mutant transposon vector and use thereof
US9017966B2 (en) 2007-05-23 2015-04-28 Nature Technology Corporation E. coli plasmid DNA production
EP2152889B1 (en) * 2007-05-29 2017-03-15 Nature Technology Corporation Vectors and methods for genetic immunization
ES2651911T3 (es) * 2007-08-14 2018-01-30 Commonwealth Scientific And Industrial Research Organisation Métodos mejorados de silenciamiento génico
US9045759B2 (en) 2009-01-21 2015-06-02 James Arthur Williams DNA plasmids with improved copy number
US9012226B2 (en) 2009-03-13 2015-04-21 Nature Technology Corporation Bacterial strains with improved plasmid stability
US9506082B2 (en) 2010-04-12 2016-11-29 Nature Technology Corporation Eukaryotic expression vectors resistant to transgene silencing
EP2788483B1 (en) * 2011-12-07 2018-06-27 Glenmark Pharmaceuticals S.A. Expression cassette
US9550998B2 (en) * 2012-08-29 2017-01-24 Nature Technology Corporation DNA plasmids with improved expression
US20150322439A1 (en) * 2012-11-19 2015-11-12 Nature Technology Corporation Replicative minicircle vectors with improved expression
CA2914604A1 (en) * 2013-06-06 2014-12-11 Novartis Ag Influenza virus reassortment
WO2017025447A1 (en) 2015-08-10 2017-02-16 Curevac Ag Method of increasing the replication of a circular dna molecule
US11230720B2 (en) 2015-10-14 2022-01-25 Audentes Therapeutics, Inc. Nucleic acid molecules containing spacers and methods of use thereof
WO2019183248A1 (en) 2018-03-21 2019-09-26 Nature Technology Corporation Viral and non-viral nanoplasmid vectors with improved production
US20220042038A1 (en) * 2018-12-20 2022-02-10 Poseida Therapeutics, Inc. Nanotransposon compositions and methods of use

Also Published As

Publication number Publication date
DK3768846T5 (da) 2024-08-19
JP7520719B2 (ja) 2024-07-23
JP2021518150A (ja) 2021-08-02
US12600984B2 (en) 2026-04-14
EP4151735A1 (en) 2023-03-22
EP3768846B1 (en) 2023-06-21
DK3768846T3 (da) 2023-07-24
LT3768846T (lt) 2023-08-10
FI3768846T3 (fi) 2023-06-30
CA3093346A1 (en) 2019-09-29
JP2024138410A (ja) 2024-10-08
ES2950736T3 (es) 2023-10-13
AU2019240068B2 (en) 2025-03-13
SG11202009009UA (en) 2020-10-29
CN112154208A (zh) 2020-12-29
AU2019240068A1 (en) 2020-10-01
US20210010021A1 (en) 2021-01-14
AU2025203312A1 (en) 2025-05-29
WO2019183248A1 (en) 2019-09-26
KR20210016330A (ko) 2021-02-15
CN120249340A (zh) 2025-07-04
EP3768846A1 (en) 2021-01-27

Similar Documents

Publication Publication Date Title
CN112154208B (zh) 产生改进的病毒和非病毒纳米质粒载体
US12215335B2 (en) Non-integrating DNA vectors for the genetic modification of cells
US10167478B2 (en) Replicative minicircle vectors with improved expression
JP7833134B2 (ja) 細菌宿主株
EP2890404A1 (en) Dna plasmids with improved expression
US20220243243A1 (en) Expression of products from nucleic acid concatemers
HK40129088A (zh) 产生改进的病毒和非病毒纳米质粒载体
WO2025160245A1 (en) Viral and non-viral nanoplasmid vectors with improved production
WO2025231315A2 (en) Bacterial host strains
HK40031637B (en) Non-integrating dna vectors for the genetic modification of cells
HK40031637A (en) Non-integrating dna vectors for the genetic modification of cells

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20230602

Address after: North Dakota

Applicant after: Aldeflon LLC

Address before: Nebraska

Applicant before: NATURE TECHNOLOGY Corp.

GR01 Patent grant
GR01 Patent grant